Education & Career

• 1979-1983: BS, College of Pharmacy, Chungbuk National University
  
• 1983-1985: MS, College of Pharmacy, Seoul National University
  
• 1988-1994: Ph.D, College of Pharmacy, University of Georgia (USA)
  
• 1994-1996: Post Doc., National Institute of Health (USA)
  
• 2000-2002: Visiting Researcher, College of Medicine, Emory University (USA)
  
• 1996-present: Professor, College of Pharmacy, Chungbuk National University

Research Areas

1. Sphingolipids?
   Ceramide synthesis occurs in the endoplasmic reticulum, and is initiated by serine palmitoyltransferase, a pyridoxal 5-phosphate dependent enzyme, to produce 3-ketosphinganine which results from the condensation of serine and palmitoyl-CoA. Ceramide can be metabolized to glycosphingolipids by a glucosylceramide synthase. Sphingolipid turnover involves removal of the sugars by exoglycosidases and the phosphorylcholine of sphingomyelin by sphingomyelinase. After removal of the sphingolipid head group, Ceramide can be either reutilized for complex sphingolipid formation or undergo further breakdown processes. Ceramide at the C-1 position was phosphorylated by ceramide kinase to ceramide 1-phosphate.
   
   
2. Adipocyte Differentiation
   Adipocytes are a major site for energy storage (in the form of triglycerides) for use during periods of caloric insufficiency. Adipocyte differentiation has important implications for human diseases such as type II diabetes, hypertension and coronary heart disease. Ceramide and ceramide 1-phosphate, bioactive sphingolipids, are also implicated in diverse cellular processes such as differentiation, cell proliferation, apoptosis and inflammation.
   
   
3. Antitumor Activity
   Myriocin, antifungal metabolite, inhibits B16F10 melanoma cell proliferation without cytotoxicity via G2/M arrest and reduces the levels of sphingolipid metabolites. The myriocin inhibition of cell proliferation in the melanoma cells may occur by blocking the sphingolipid biosynthesis pathway and depleting sphingosine, ceramide and ceramide 1-phosphate.
   

Selected Publications

1. Yoo, H.S.; Hong J.T.; Lee, Y.M.; Yun, Y.P.; Lee, Y.S.; Choi, K.M.; Choi, M.H.; Ji, S.Y.; Yoo, J.M. Simultaneous HPLC Analysis of Ceramide and Dihydroceramide in Human Hairs. Arch. Pharm. Res. 2009, 32, 1795-1801.
   
2. Yoo, H.S.; Shin, H.W.; Kim, D.; Lee, Y.S.; Lee, B.J.; Kim, J.S.; Jang, S.; Lim, H.; Lee, Y.; Oh, S. Alteration of sphingolipid metabolism and pSTAT3 expression by dietary cholesterol in the gallbladder of hamsters. Arch. Pharm. Res. 2009, 32, 1253-1262.
   
3. Yoo, H.S.; Yun, Y.P.; Pyo, M.Y.; Hong J.T.; Im, J.H., Jin, Y.R.; Lee, J.J.; Yu, J.Y.; Han, X.H.; Im, S.H. Antiplatelet activity of β-carboline alkaloids from Perganum harmala: A possible mechanism through inhibiting PLCγ2 phosphorylation. Vascul. Pharmacol. 2009, 50, 147-152.
   
4. Yoo, H.S.; Yoon, C.H.; Kim, M.J.; Park, M.T.; Byun, J.Y.; Lee, Y.M.; Hyun, J.W.; Lee, S.J. Activation of p38 Mitogen-Activated Protein Kinase Is Required for Death Receptor-Independent Caspase-8 Activation and Cell Death in Response to Sphingosine. Mol. Cancer Res. 2009, 7, 361-370.
   
5. Yoo, H.S.; Lee, Y.M.; Yim, Y.H.; Jin, Y.X.; Shi, L.H.; So, H.Y.; Kihara, A.; Igarshi, Y. A sphingosine kinase activity assay using direct infusion electrospray ionization tandem mass spectrometry. Anal. Biochem. 2008, 380, 35-40.
   
6. Yoo, H.S.; Lee, Y.M.; Oh, S.; Suh, S.H.; Jang, S. Changes in iNOS, GFAP and NR1 expression in various brain regions and elevation of sphingosine-1-phosphate in serum after immobilized stress. Neurochem. Res. 2008, 33, 842-851.
   
7. Yoo, H.S.; Mitsutake, S.; Yokose, U.; Kato, M.; Matsuoka, I.; Yoo, J.M.; Kim, T.J.; Fujimoto, K.; Ando, Y.; Sugiura, M.; Kohama, T.; Igarashi, Y. The generation and behavioral analysis of ceramide kinase-null mice, indicating a function in cerebellar Purkinje cells. Biochem. Biophys. Res. Commun. 2007, 363, 519-524.
   
8. Yoo, H.S.; Kim, T.J.; Jeon, J.; Jin, Y.R.; Son, D.J.; Hong J.T.; Ryu, C.K.; Shin, H.S.; Lee, K.H.; Yun, Y.P. Effects of KTJ740, a novel Antithrombotic agent, on platelet-derived growth factor-induced rat aortic smooth muscle cell proliferation and cell cycle progression. J. Cardiovasc. Pharmacol. 2007, 49, 280-286.
   
9. Yoo, H.S.; Burenjargal, M.; Lee, Y.S.; Yoo, J.M.; Kim, Y.C.; Lee, Y.M.; Oh, S.; Yun, Y.P.; Hong J.T.; Chung, Y.B.; Moon, D.C. Endogenous sphingolipid metabolites related to the growth in Sphingomonas chungbukensis. Arch. Pharm. Res. 2007, 30, 317-322.
   
10. Yoo, H.S.; Jang, S.; Lee, J.H.; Choi, K.R.; Kim, D.; Oh, S. Cytochemical alterations in the rat retina by LPS administration. Neurochem. Res. 2007, 32, 1-10.
    
11. Yoo, H.S.; Lee, Y.M.; Kim, D.H.; Kie, J.H.; Jang, S.; Oh, S. Elevation of sphinganine 1-phosphate as a predictive biomarker for fumonisin exposure and toxicity in mice. J. Toxicol. Environ. Health Part A. 2006, 69, 2071-2082.
    
12. Yoo, H.S.; Park, H.K.; Park, E.C.; Bae, S.W.; Park, M.Y.; Kim, S.W.; Tudev, M.; Ko, Y.H.; Choi, Y.H.; Kim, S.; Lee, B.B.; Yoon, J.B.; Park, J.E.; Kim, Y.W.; Kim, D.I. expression of heat shock protein 27 in human atherosclerotic plaques and increased plasma level of heat shock protein 27 in patients with acute coronary syndrome. Circulation. 2006, 114, 886-893.
    
13. Yoo, H.S.; Kim, Y.J.; Suh, S.H.; Oh, S.; Park, H.S.; Lee, H.Y.; Ha, E.H. Reduced L-arginine level and decreased placental eNOS activity in preeclampsia. Placenta. 2006, 27, 438-444.
    
14. Yoo, H.S.; Yun, Y.P.; Hong J.T.; Lee, Y.M.; Lee, Y.S.; Choi, H.K.; Oh, S.; Yoo, J.M. Protection of LLC-PK1 cells against hydrogen peroxide-induced cell death by modulation of ceramide level. Arch. Pharm. Res. 2005, 28, 311-318.
    
15. Yoo, H.S.; Lee, Y.S.; Park, J.E.; Bae, S.W.; Stuhlinger, M.C.; Lee, S.H.; Choi, Y.H.; Pachinger, O.; Choi, B.Y.; Park, H.K.; Yu, K.H. Plasma asymmetric dimethylarginine concentrations in newly diagnosed patients with acute myocardial infarction or unstable angina pectoris during two weeks of medical treatment. Am. J. Cardiol. 2005, 95, 729-733.
    
16. Interleukin-32 gamma attenuates ethanol-induced liver injury by the inhibition of cytochrome P450 2E1 e-pression and inflammatory responses, Clinical Science, 2015
17. Memory impairment in estrogen receptor alpha knockout mice through accumulation of amyloid-beta peptides, Molecular Neurobiology, 2015
18. Anti-cancer effect of N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2,3-dihydronaphtho[1,2-b]furan-2-carboxamide, a novel synthetic compound, Molecular Carcinogenesis, 2016
19. Dodeca-2(E),4(E)-dienoic acid isobutylamide enhances glucose uptake in 3T3-L1 cells via activation of Akt signaling, Molecular and Cellular Biochemistry, 2017
20. Activated natural killer cells mediate the suppressive effect of interleukin-4 on tumor development via STAT6 activation in an atopic condition melanoma model1,2, Neoplasia, 2017
21. 3,3-Diindolylmethane Enhances Glucose Uptake Through Activation of Insulin Signaling in 3T3-L1 Adipocytes, Obesity, 2018

Patents

1. 알칼라인 포스파타아제의 탈인산화 후 오-프탈알데히드 유도체를 사용한 생체내 스핑고지질 1-인산과 스핑고지질의 동시정량 분석법 (특허등록:제0471943호)
   
2. 신남알데히드 유도체 화학물을 함유하는 염증성 질환의 예방 및 치료용 약학조성물 (특허등록:제0676761호)
   
3. 토마토로부터 리코펜을 직접 추출하는 방법(특허등록:제0692253호)
   
4. 내부 표준물질을 이용한 생체시료내 세라마이드의 정량분석방법(특허등록:제0892988호)
   
5. 파이토세라마이드를 포함하는 뇌혈관질환의 예방 및 치료용 의약 조성물 및 식품 조성물(특허출원:제20080079886호)

Education & Career

• 2000-2008: DVM, College of Veterinary Medicine, Chonbuk National University
• 2008-2011: PhD, Department of Pathology, College of Veterinary Medicine, Chonbuk National University (PI: Bumseok Kim)
• 2012-2015: Postdoctoral Fellow (PI: Ekihiro Seki), Department of Pathology, University of California, San Diego, School of Medicine, CA, USA
• 2015-2016: Postdoctoral Scientist (PI: Ekihiro Seki), Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA
• 2016-Present: Assistant Professor, College of Pharmacy, Chungbuk National University

Research Areas

1. Target Discovery and Validation in Non-alcoholic Steatohepatitis (NASH)

   

2. Identification of hepatocyte-derived secretome in transition from simple steatosis to NASH

   

3. Mitochondrial Quality Control as a Therapeutic Target in Fatty Liver and metabolic syndrome

   

Selected Publications

I. Primary authorships (First author or Corresponding author):
P-1. Hepatology 2014 Jul;60(1):237-49. (IF: 14.079)
P-2. Journal of Clinical Investigation 2014 Aug;124(8):3566-78. (IF: 13.251)
P-3. Gastroenterology 2015 Jan;148(1):252-254. (IF: 20.773)
P-4. American Journal of Pathology 2018 Nov;188(11):2574-2588. (IF: 4.069)
P-5. Antioxidants & Redox Signaling 2019 May; Epub ahead of print (IF: 7.407)


II. Contributed authorships (co-author):
C-1. Nature Communications 2014 Jul 21;5:4451. (IF: 12.353)
C-2. Hepatology 2014 Feb;59(2):483-95. (IF: 14.079)
C-3. Gastroenterology 2013 May;144(5):1042-1054. (IF: 20.773)
C-4. Theranostics. 2018 Aug 7;8(16):4409-4428. (IF: 8.537)
C-5. Science Translational Medicine 2019 Jun; Epub ahead of print (IF: 16.71)